BioAscent is a CRO with extensive expertise in the constituent disciplines of drug discovery. We combine these disciplines together to enable effective delivery of fully integrated drug discovery services to our customers. Our scientists work in closely-knit teams on a single site and are accustomed to working closely with customers from around the world to understand what is required, to drive progress and to reach key milestones.
Working in collaboration with partners at the German Cancer Research Center within the European Lead Factory project (ELF), BioAscent scientists helped discover potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases. This work has been published in ChemMedChem.
“More importantly, the scientists who were involved in the hit development stage, were fully committed to the success of the project, bringing their own ideas and solutions, which made my role as project owner very comfortable. I would be very happy to work with them again.”
Dr Aubry Miller, Cancer Drug Discovery/Wirkstoffforschung Group Leader, German Cancer Research Center (DKFZ)